Journal of Addiction Medicine最新文献

筛选
英文 中文
A Brief Intervention on Alcohol Use Disorder Is Associated With Treatment Access for Inpatients With Alcohol-associated Liver Disease. 对酒精相关肝病住院患者进行酒精使用障碍简短干预与获得治疗有关。
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-08-16 DOI: 10.1097/ADM.0000000000001371
Patrick A Twohig, Alena Balasanova, Lauren Cooper, Michelle Le, Nathalie Khoury, Wuittporn Manatsathit, Marco Olivera, Thoetchai Bee Peeraphatdit
{"title":"A Brief Intervention on Alcohol Use Disorder Is Associated With Treatment Access for Inpatients With Alcohol-associated Liver Disease.","authors":"Patrick A Twohig, Alena Balasanova, Lauren Cooper, Michelle Le, Nathalie Khoury, Wuittporn Manatsathit, Marco Olivera, Thoetchai Bee Peeraphatdit","doi":"10.1097/ADM.0000000000001371","DOIUrl":"10.1097/ADM.0000000000001371","url":null,"abstract":"<p><strong>Background: </strong>Alcohol-associated liver disease (ALD) is the most common indication for liver transplantation in the United States. Alcohol use disorder (AUD) treatment is recommended in all patients with ALD and AUD, but it remains underutilized.</p><p><strong>Aims: </strong>To identify predictors of AUD treatment and to assess 30-day readmission, return to drinking, and 1-year transplant-free survival.</p><p><strong>Methods: </strong>Retrospective single-center cohort study of consecutive patients hospitalized with ALD and AUD between 2018 and 2020. Patients who died or were lost to follow-up at 90 days after hospitalization were excluded. AUD treatment was defined as receiving medication or participating in residential, outpatient, or support groups within 90 days of discharge.</p><p><strong>Results: </strong>One hundred nine patients were included. Mean age was 51.7 years, and 63% were male. Fifty-six (51%) patients received AUD treatment, and 23 (21%) patients received more than one treatment. Predictors of AUD treatment were younger age (OR, 1.07 [95% CI, 1.04-1.12]; P < 0.001), gastroenterology/hepatology consult (AOR, 8.54 [95% CI, 2.55-39.50]; P = 0.0002), addiction psychiatry consult (AOR, 2.77 [95% CI, 1.16-6.84]; P = 0.02), and a brief AUD intervention (AOR, 18.19 [95% CI, 3.36-339.07]; P = 0.0001). Cirrhosis decompensation, MELD-Na score, and insurance status were not associated with treatment. Thirty-one patients (28.4%) were readmitted, and 29 (26.6%) remained abstinent 30 days from discharge. Patients who received treatment had improved transplant-free survival (HR, 0.44, P = 0.04).</p><p><strong>Conclusion: </strong>A brief intervention on AUD had the strongest association with receiving AUD treatment in our cohort. Further efforts to incorporate brief interventions when offering AUD treatment to patients with ALD may be beneficial.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"35-40"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cannabinoid Hyperemesis Syndrome Presumed Secondary to CBD Use: A Case Report. 推测因使用 CBD 而继发的大麻素吐逆综合征:病例报告。
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-09-02 DOI: 10.1097/ADM.0000000000001378
Emilie Lefebvre, Luc Simons, Mélanie Duval, Edouard-Jules Laforgue, Caroline Victorri-Vigneau
{"title":"Cannabinoid Hyperemesis Syndrome Presumed Secondary to CBD Use: A Case Report.","authors":"Emilie Lefebvre, Luc Simons, Mélanie Duval, Edouard-Jules Laforgue, Caroline Victorri-Vigneau","doi":"10.1097/ADM.0000000000001378","DOIUrl":"10.1097/ADM.0000000000001378","url":null,"abstract":"<p><strong>Introduction: </strong>Cannabinoid hyperemesis syndrome is characterized by recurrent episodes of severe nausea and vomiting, often associated with prolonged and excessive cannabis use. With the recent legalization and rising consumption of cannabidiol (CBD) in Europe and the United States, concerns have emerged about its potential role in triggering similar symptoms.</p><p><strong>Case report: </strong>A 32-year-old male with a history of cannabis, tobacco and alcohol use disorder experienced multiple cyclic vomiting episodes after switching from cannabis to CBD. Initially, the patient presented with abdominal pain and vomiting after ceasing cannabis use, with symptoms alleviated by hot showers. Three months later, similar symptoms reappeared despite abstinence from cannabis but regular CBD consumption. Over the next 6 months, recurrent episodes of abdominal pain and vomiting persisted with daily CBD use but no cannabis consumption. Clinical data, laboratory results, and treatment responses were analyzed to investigate the connection between CBD consumption and symptom onset.</p><p><strong>Discussion: </strong>The pathophysiology of cannabis-induced cyclic vomiting is poorly understood. Hypotheses include tetrahydrocannabinol accumulation in adipose tissue, pyrolytic conversion of CBD into tetrahydrocannabinol, and CBD's intrinsic effects, particularly its interaction with transient receptor potential vanilloid 1 receptors. Our analysis suggests that high doses of CBD may activate transient receptor potential vanilloid 1 receptors, inducing proemetic effects.</p><p><strong>Conclusions: </strong>Although the connection between CBD and cyclic vomiting remains uncertain, it warrants further investigation. The increasing use of CBD, perceived as a safe dietary supplement, underscores the need to understand its potential health impacts better.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"115-117"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. 与监狱合作为阿片类药物使用障碍提供基于社区的药物治疗:来自mod治疗提供者的定性观点。
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-12-02 DOI: 10.1097/ADM.0000000000001420
Ekaterina Pivovarova, Bianca Y Planas Garcia, Peter D Friedmann, Thomas J Stopka, Claudia Santelices, Elizabeth A Evans
{"title":"Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers.","authors":"Ekaterina Pivovarova, Bianca Y Planas Garcia, Peter D Friedmann, Thomas J Stopka, Claudia Santelices, Elizabeth A Evans","doi":"10.1097/ADM.0000000000001420","DOIUrl":"10.1097/ADM.0000000000001420","url":null,"abstract":"<p><strong>Objectives: </strong>As carceral settings increasingly offer medications for opioid use disorders (MOUD), community-based providers will need to navigate relationships with correctional agencies to ensure continuity of MOUD upon release. Although collaboration has been identified as critical between agencies, limited research is available that details how providers can work with jails. We describe the perspectives of MOUD providers about their experiences collaborating with jails that had recently begun to offer MOUD.</p><p><strong>Methods: </strong>We conducted hour-long interviews with 36 MOUD providers from 18 community-based agencies. Exploration, Preparation, Implementation, and Sustainment (EPIS) concepts informed data collection and analysis.</p><p><strong>Results: </strong>MOUD providers described agency-specific (inner context) factors that facilitated collaboration, including staffing (employing staff with knowledge of co-occurring conditions) and agency culture (adaptability to change, recognition of gaps in services, being judgment-free). Providers also reported external factors as facilitators, such as broad community support of MOUD services and provision of training about MOUD to jail staff. Holding regular meetings, with a dedicated contact person, helped to overcome communication problems. However, the fragmentation of in-jail treatment services, exacerbated by jails' contracting with different healthcare providers, made it difficult to coordinate re-entry and establish agency relationships. Actively and intentionally building interagency partnerships and collaborating across interagency cultural and structural differences were bridging factors that developed and sustained collaborations.</p><p><strong>Conclusions: </strong>Our findings offer promising suggestions for establishing collaborations with carceral partners, including assessing internal agency conditions, seeking external community supports, committing to actively engaging and sustaining collaborations, and using interagency differences to develop mutually beneficial relationships.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"95-101"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers and Facilitators to Accessing Opioid Agonist Therapy for Street-involved Adolescents and Young Adults in Vancouver. 温哥华街头青少年获得阿片类激动剂治疗的障碍和促进因素。
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-08-27 DOI: 10.1097/ADM.0000000000001361
Kat Gallant, Preety Nijjar, Kora DeBeck, Michelle Cui, Thomas Kerr
{"title":"Barriers and Facilitators to Accessing Opioid Agonist Therapy for Street-involved Adolescents and Young Adults in Vancouver.","authors":"Kat Gallant, Preety Nijjar, Kora DeBeck, Michelle Cui, Thomas Kerr","doi":"10.1097/ADM.0000000000001361","DOIUrl":"10.1097/ADM.0000000000001361","url":null,"abstract":"<p><strong>Objective: </strong>Opioid agonist therapy (OAT) remains the first-line therapy for people with opioid use disorder. Whereas overdose rates among adolescents and young adults (AYAs) remain high, little is known about their access to OAT. Therefore, we sought to evaluate factors that shape access to OAT among AYAs aged 14 to 26 years.</p><p><strong>Methods: </strong>Data were derived from the At-Risk Youth Study, a prospective cohort study that involves street-involved AYAs who use illicit substances in Vancouver, Canada. Generalized estimating equations were used to identify factors associated with OAT enrollment from September 2005 to October 2021.</p><p><strong>Results: </strong>A total of 759 AYAs reported at least weekly opioid or OAT use, with a median age of 23 years and 65.7% self-identifying as male. At baseline, 147 participants (19.4%) were on OAT, and another 199 (26.2%) initiated OAT during study follow-up (median number of follow-up visits, 5 [Q1-Q3, 2.5-8]). In a multivariable analysis, being <19 years old (adjusted odds ratio [AOR], 0.40; 95% confidence interval [CI], 0.23-0.71), Indigenous ancestry (OR, 0.72; 95% CI, 0.52-1.00), homelessness (AOR, 0.65; 95% CI, 0.54-0.77), drug dealing (AOR, 0.73; 95% CI, 0.61-0.87), daily opioid use (AOR, 0.47; 95% CI, 0.40-0.55), and nonfatal overdose (AOR, 0.73; 95% CI, 0.60-0.89) were negatively associated with OAT use.</p><p><strong>Conclusions: </strong>This study identified a low rate of OAT access among AYAs. Adolescents and young adults were less likely to be on OAT if they were <19 years old, Indigenous, and possessed certain risk markers. These findings highlight the need for mitigation strategies to facilitate OAT access for this population and for additional harm reduction measures to support AYAs who do not want to use OAT.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"105-108"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-label, Nonrandomized Clinical Trial. 使用低剂量丁丙诺啡转移美沙酮-丁丙诺啡:一项开放标签、非随机临床试验。
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-12-03 DOI: 10.1097/ADM.0000000000001379
Chris Tremonti, James Blogg, Nazila Jamshidi, Ricky Harjanto, Nicholas Miles, Charlotte Ismay, Robert Page, Llew Mills, Nicholas Buckley, Varan Perananthan, Nicholas Lintzeris, Paul Haber
{"title":"Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-label, Nonrandomized Clinical Trial.","authors":"Chris Tremonti, James Blogg, Nazila Jamshidi, Ricky Harjanto, Nicholas Miles, Charlotte Ismay, Robert Page, Llew Mills, Nicholas Buckley, Varan Perananthan, Nicholas Lintzeris, Paul Haber","doi":"10.1097/ADM.0000000000001379","DOIUrl":"10.1097/ADM.0000000000001379","url":null,"abstract":"<p><strong>Aims: </strong>To compare a low-dosing protocol to standard practice for methadone-buprenorphine transfers.</p><p><strong>Methods: </strong>We undertook a nonrandomized open-label clinical trial across 8 sites from NSW, Australia. Participants prescribed methadone wishing to transfer to buprenorphine could either choose or be randomized to a low-dose transfer or standard care transfer as per NSW health guidelines. The low-dose protocol started at 0.2 mg BD and increased to 16 mg on day 6, with flexible dosing thereafter. The primary outcome was continuation of buprenorphine 1 week post-transfer. Binary logistic regression was used to access the primary outcome with demographic differences between the groups included as covariates.</p><p><strong>Results: </strong>There were 117 participants who commenced the study, 101 in the low-dose arm and 16 in standard care. Mean methadone dose was 82 mg in the low-dose arm and 46 mg in standard care. The primary outcome was met by 81 participants in the low-dose arm (80%) and 13 participants in standard care (81%). There was no significant between-arm difference in the odds of the primary outcome (OR = 2.22; 95% CI: 0.45-10.91; P = 0.327). Four participants (4%) in the low-dose arm experienced precipitated withdrawal against 1 (6%) in standard care. Higher methadone dose decreased the odds of successful transfer by 20% (OR = 0.8 per 10 mg methadone; 95% CI: 0.7-0.99; P = 0.04). Withdrawal scores between the 2 arms were similar.</p><p><strong>Conclusions: </strong>We were unable to detect a difference between low dosing and standard care for methadone to buprenorphine transfers. Increasing methadone dose was a predictor of success; setting (ambulatory or inpatient) was not.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"75-82"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of COVID-19 on Substance Use and Related Consequences Among Patients in Office-based Opioid Use Disorder Treatment. COVID-19 对接受办公室阿片类药物使用障碍治疗患者的药物使用及相关后果的影响。
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-08-05 DOI: 10.1097/ADM.0000000000001367
Zoe M Weinstein, Kara M Magane, Sara Lodi, Alicia S Ventura, Angela R Bazzi, Juliana Blodgett, Sarah Fielman, Melissa Davoust, Margaret G Shea, Clara A Chen, Anna Cheng, Jacqueline Theisen, Samantha Blakemore, Richard Saitz
{"title":"The Impact of COVID-19 on Substance Use and Related Consequences Among Patients in Office-based Opioid Use Disorder Treatment.","authors":"Zoe M Weinstein, Kara M Magane, Sara Lodi, Alicia S Ventura, Angela R Bazzi, Juliana Blodgett, Sarah Fielman, Melissa Davoust, Margaret G Shea, Clara A Chen, Anna Cheng, Jacqueline Theisen, Samantha Blakemore, Richard Saitz","doi":"10.1097/ADM.0000000000001367","DOIUrl":"10.1097/ADM.0000000000001367","url":null,"abstract":"<p><strong>Objectives: </strong>The COVID-19 pandemic led to increased substance-related morbidity and mortality and transformed care for opioid use disorder (OUD). We assessed the perceived impacts of the pandemic on substance use and related consequences among patients in office-based addiction treatment (OBAT).</p><p><strong>Methods: </strong>We recruited patients with OUD on buprenorphine from July 2021 to July 2022, with data collection at baseline and 6 months. Exposures of interest were the following 6 domains potentially impacted by COVID-19: personal or family infection, difficulty accessing healthcare/medication, economic stressors, worsening physical or mental health, social isolation, and conflicts/disruptions in the home. Outcomes were past 30-day alcohol and other substance use, increased use, and substance-related consequences at baseline and 6 months. Generalized estimating equations Poisson regression models quantified associations between increasing impact domain scores and relative risks of each outcome.</p><p><strong>Results: </strong>All participants (N = 150) reported at least one domain negatively impacted by COVID-19 at both time points. Higher \"worsening physical or mental health\" domain scores were associated with increased relative risk of recent alcohol or drug use (adjusted risk ratio [aRR] 1.04, 95% confidence interval [CI]: 1.01-1.07). Relative risks of experiencing substance-related consequences increased with higher scores in the domains of economic stressors (aRR 1.07, 95% CI: 1.02-1.13), difficulty accessing healthcare/medication (aRR 1.11, 95% CI: 1.04-1.19), and worsening physical or mental health (aRR 1.08, 95% CI: 1.04-1.12).</p><p><strong>Conclusions: </strong>Among patients with OUD, stressors from COVID-19 were common. Three life domains impacted by COVID-19 appeared to be associated with consequential substance use, highlighting opportunities to address barriers to healthcare access and economic stressors.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"12-19"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141889254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trauma Prevalence and Its Association With Health-related Quality of Life in Pregnant Persons With Opioid Use Disorder. 阿片类药物使用失调症孕妇的创伤发生率及其与健康相关的生活质量的关系。
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-08-06 DOI: 10.1097/ADM.0000000000001366
T John Winhusen, Frankie Kropp, Shelly F Greenfield, Elizabeth E Krans, Daniel Lewis, Peter R Martin, Adam J Gordon, Todd H Davies, Elisha M Wachman, Antoine Douaihy, Kea Parker, Xie Xin, Ali Jalali, Michelle R Lofwall
{"title":"Trauma Prevalence and Its Association With Health-related Quality of Life in Pregnant Persons With Opioid Use Disorder.","authors":"T John Winhusen, Frankie Kropp, Shelly F Greenfield, Elizabeth E Krans, Daniel Lewis, Peter R Martin, Adam J Gordon, Todd H Davies, Elisha M Wachman, Antoine Douaihy, Kea Parker, Xie Xin, Ali Jalali, Michelle R Lofwall","doi":"10.1097/ADM.0000000000001366","DOIUrl":"10.1097/ADM.0000000000001366","url":null,"abstract":"<p><strong>Objectives: </strong>Trauma screening is recommended for pregnant persons with opioid use disorder (OUD), but there is limited literature on screening results from buprenorphine treatment. This study's objectives were to 1) describe the types, and severity, of traumatic events reported and 2) evaluate the associations between trauma and health-related quality of life (HRQoL).</p><p><strong>Methods: </strong>Baseline data from an ongoing trial were analyzed. Participants were 155 pregnant persons with OUD receiving, or enrolling in, buprenorphine treatment at one of 13 sites. The experience, and relative severity, of 14 high magnitude stressors were assessed with the trauma history screen. The Patient-Reported Outcomes Measurement Information System-29+2 was used to assess 8 HRQoL domains.</p><p><strong>Results: </strong>Traumatic stressors were reported by 91% of the sample (n = 155), with 54.8% reporting a lifetime persisting posttraumatic distress (PPD) event and 29.7% reporting a childhood PPD event. The most prevalent lifetime PPD event was sudden death of a close family/friend (25.8%); physical abuse was the most prevalent childhood PPD event (10.3%). Participants with lifetime PPD, relative to no PPD, reported significantly greater pain interference ( P = 0.02). Participants with childhood PPD, relative to no PPD, had significantly worse HRQoL overall ( P = 0.01), and worse pain intensity ( P = 0.002), anxiety ( P = 0.003), depression ( P = 0.007), fatigue ( P = 0.002), and pain interference ( P < 0.001).</p><p><strong>Conclusions: </strong>A majority of pregnant persons enrolled/enrolling in buprenorphine treatment reported persisting posttraumatic distress with sudden death of close family/friend being the most prevalent originating event; clinicians should consider the impact that the opioid-overdose epidemic may be having in increasing trauma exposure in patients with OUD.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"20-25"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perinatal Naloxone Care Practices: Survey Results From Persons With OUD and Providers. 围产期纳洛酮护理实践:来自 OUD 患者和医疗服务提供者的调查结果。
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-09-02 DOI: 10.1097/ADM.0000000000001376
Nichole Nidey, Heather C Kaplan, Susan Ford, Mona Prasad, Carole Lannon
{"title":"Perinatal Naloxone Care Practices: Survey Results From Persons With OUD and Providers.","authors":"Nichole Nidey, Heather C Kaplan, Susan Ford, Mona Prasad, Carole Lannon","doi":"10.1097/ADM.0000000000001376","DOIUrl":"10.1097/ADM.0000000000001376","url":null,"abstract":"<p><strong>Objective: </strong>Little is known about naloxone care practices for peripartum persons from the patient or provider perspectives. The objective of this study was to survey peripartum persons and providers about naloxone-related practices.</p><p><strong>Methods: </strong>Individuals who had an OUD diagnosis during a pregnancy and Ohio healthcare professionals who provide care for peripartum patients with OUD and/or infants with prenatal exposure to opioids were eligible for this study. Patient experiences were assessed through a survey codeveloped with members with lived experience of opioid use disorder. Provider perspectives were examined through a survey codeveloped by the Ohio Perinatal Quality Collaborative. Descriptive statistics and logistic regression were used to examine the proportion of participants who received or provided naloxone care practices and the effect on having a naloxone kit during the perinatal period.</p><p><strong>Results: </strong>Of the 100 peripartum participants with opioid use disorder, 24% reported receiving naloxone from their prenatal care provider and 48% reported ever having a naloxone kit during the perinatal period. Of the 63 maternal care provider participants, 32 (49%) reported discussing or prescribing naloxone to pregnant patients. Of the 62 pediatric provider participants, 10 (16%) reported that they provide naloxone information to parenting individuals of their patients.</p><p><strong>Conclusion: </strong>Study results demonstrate critical gaps in naloxone care practices for peripartum persons, emphasizing the need for targeted interventions at the patient, clinician, practice, and system levels.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"62-67"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Smoking Abstinence and Depression and Anxiety Symptoms After Hospital Discharge: The Helping HAND 4 Trial. 出院后戒烟与抑郁和焦虑症状之间的关系:Helping HAND 4 试验
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-08-08 DOI: 10.1097/ADM.0000000000001358
Catherine S Nagawa, Nancy A Rigotti, Yuchiao Chang, Douglas E Levy, Joanna M Streck, Thomas Ylioja, Scott S Lee, Hilary A Tindle
{"title":"Association Between Smoking Abstinence and Depression and Anxiety Symptoms After Hospital Discharge: The Helping HAND 4 Trial.","authors":"Catherine S Nagawa, Nancy A Rigotti, Yuchiao Chang, Douglas E Levy, Joanna M Streck, Thomas Ylioja, Scott S Lee, Hilary A Tindle","doi":"10.1097/ADM.0000000000001358","DOIUrl":"10.1097/ADM.0000000000001358","url":null,"abstract":"<p><strong>Objectives: </strong>Some people who stop smoking experience improved mood, but few studies have examined this relationship after hospitalization or accounted for concomitant substance use and psychological factors. We examined associations between smoking abstinence after a hospital discharge and change in depression and anxiety symptoms.</p><p><strong>Methods: </strong>We conducted a secondary analysis of data from the Helping HAND 4 smoking cessation trial, which enrolled people who used tobacco when admitted to three academic medical center general hospitals. Participants (n = 986) were categorized as continuously abstinent (CA) or not. We used linear and logistic regression to model continuous and binary measures of depression (Patient Health Questionnaire [PHQ-8] ≥/<10), and anxiety (Generalized Anxiety Disorder Assessment [GAD-7], ≥/<8) over 6 months, adjusting for baseline mood, psychological factors, and substance use. Binary outcomes were defined using established clinical thresholds to aid in the clinical interpretation of the results.</p><p><strong>Results: </strong>Mean age was 52.3 years, 56.5% were female, and the baseline mean cigarettes/day was 16.2 (SD: 3.2). In the adjusted analyses, depression and anxiety scores improved more in CA than non-CA participants over 6 months (difference-in-improvement, 2.43 [95% CI: 1.50-3.36] for PHQ-8; 3.04 [95% CI: 2.16-3.93] for GAD-7). At 6 months, CA participants were more likely to have a PHQ-8 score <10 (aOR = 2.07 [95% CI: 1.36-3.16]) and a GAD-7 score <8 (aOR = 2.90 [95% CI: 1.91-4.39]).</p><p><strong>Conclusions: </strong>Individuals who were CA, compared to those who were not, had fewer depression and anxiety symptoms at 6 months, and were twice as likely to score below the population screening thresholds for major depression and anxiety disorders. Clinicians should emphasize the association between continuous abstinence and improved mood symptoms after hospital discharge.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"4-11"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medications for Alcohol Use Disorder Among Birthing People With an Alcohol-related Diagnosis. 在被诊断患有酒精相关疾病的分娩人群中使用药物治疗酒精使用障碍。
IF 4.2 3区 医学
Journal of Addiction Medicine Pub Date : 2025-01-01 Epub Date: 2024-09-04 DOI: 10.1097/ADM.0000000000001372
Sarah C M Roberts, Guodong Liu, Mishka Terplan
{"title":"Medications for Alcohol Use Disorder Among Birthing People With an Alcohol-related Diagnosis.","authors":"Sarah C M Roberts, Guodong Liu, Mishka Terplan","doi":"10.1097/ADM.0000000000001372","DOIUrl":"10.1097/ADM.0000000000001372","url":null,"abstract":"<p><strong>Objectives: </strong>Although safety and effectiveness of medications for alcohol use disorder (AUD) are well established for adults, literature on these medications in pregnancy is limited. Given known adverse effects of untreated AUD during pregnancy, clinicians and researchers have recently begun to call for reconsidering use of medications for AUD in pregnancy. Thus, we sought to estimate the proportion of birthing people with an alcohol-related diagnosis who received a prescription for medication related to AUD treatment.</p><p><strong>Methods: </strong>Data were from Meritive MarketScan, a national private insurance claims database. The study cohort included birthing people aged 25-50 who gave birth to a singleton in the United States between 2006 and 2019 and were matched with an infant. Variables included an alcohol-related diagnosis within a year of birth and receiving a prescription for a medication related to AUD treatment. We calculated proportions with alcohol-related diagnoses who received any AUD medication and each medication type.</p><p><strong>Results: </strong>Of 1,432,979 birthing person-infant dyads, 2517 (0.18%) had an alcohol-related diagnosis. Of those with an alcohol-related diagnosis, 8.70% (n = 219) received any medication. The most common was gabapentin (4.69%, n = 118), with benzodiazepines for withdrawal as the second most common (2.19%, n = 55). Approximately 2% received naltrexone (1.91%, n = 48) and/or disulfiram (1.39%, n = 35); 0.56% (n = 14) received acamprosate. No one with an alcohol-related diagnosis received phenobarbital. Almost all medications were received postpartum.</p><p><strong>Conclusions: </strong>Very few pregnant/postpartum people with alcohol-related diagnoses are prescribed medications related to AUD treatment. Research is needed to examine whether benefits of these medications during pregnancy outweigh harms.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"41-46"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信